| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
ekekeg
Veteran |
28-Aug-2007 12:32
|
|
x 0
x 0 Alert Admin |
WOHOO, alamak, this counter looks condemned. Good days didn't go up and bad days followed to come down. Counting the number of tanks, there are 10 down days already as shown by the candlestick chart. I'm having nothing to do with this counter oredi. Divested |
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
26-Aug-2007 14:26
Yells: "Female TA nut" |
|
x 0
x 0 Alert Admin |
TA charts are bearish looking still.. |
| Useful To Me Not Useful To Me | |
|
|
|
|
investor
Senior |
25-Aug-2007 21:22
|
|
x 0
x 0 Alert Admin |
On the contrary, medical products like Biosensors is quite immune to the economy - If you have a heart attack, you need their product, regardless of the economy. Also, ONCE you get APPROVAL to mkt the product, there is practically high barriers to entry for their competitors - in fact, no one else can sell these products without approval. Maybe that is the reason why JW Medical's growth is so strong in China - They have China's FDA approval, for which I believe, only a few companies have. On top of that, If I need to use a drug eluting stent, why choose Johnson & Johnson's Cypher stent, with the Sirolimus drug, BUT with a PERMANENT polymer (which is suspected to cause stent thrombosis - blood clotting) - when I can choose JW medical DES, which has the same Sirolimus drug, BUT with a degradable polymer ? IT is an obvious choice. Also, I believe that the Cypher stent will come with import tax - thus making the JW medical Excel stent even more economical. (also, manufacturing is done in China, making it even more cost competitive). Having said that, the price is indeed volatile, even more so, with the recent subprime crsis. It takes a stout heart to have faith in this counter. |
| Useful To Me Not Useful To Me | |
|
Pension
Elite |
25-Aug-2007 19:55
|
|
x 0
x 0 Alert Admin |
This counter is very sensitive to USA economy news, one bad news can cause the counter to drop 20 to 40 cents. The risk and liabilities of this company is high, they have to pump in money for research,testing,patent and endorsement of their product. If their product is proven and defect free, they can make trillion of dollars. |
| Useful To Me Not Useful To Me | |
|
investor
Senior |
25-Aug-2007 19:22
|
|
x 0
x 0 Alert Admin |
JW Medical's Q1 results was 17.3 million RMB, while its Q2 results was 31.92 Million RMB - an increase of 84 % quarter on quarter. (information available in Shandong Weigao's financial results.) In US dollars terms, Q1 results was approx US$2.37 m and Q2 results was approx US$4.3 m. - half yr07 = US$6.67m. Assuming flat growth going forward, JW medical's full year results will be US$13.34m. Biosensors's half share of the profit will be US$6.67m. For info. |
| Useful To Me Not Useful To Me | |
|
|
|
|
novena_33
Veteran |
22-Aug-2007 21:49
|
|
x 0
x 0 Alert Admin |
bro some time...i think i need their product tooo 
|
| Useful To Me Not Useful To Me | |
|
Pension
Elite |
22-Aug-2007 12:10
|
|
x 0
x 0 Alert Admin |
I think both will have heart attack end of the day. |
| Useful To Me Not Useful To Me | |
|
Fairygal
Veteran |
21-Aug-2007 17:38
|
|
x 0
x 0 Alert Admin |
Yes, within the next 3 days before you are due to pay up, you can contra. You can either buy low, sell high, thus a profit, or buy low , sell lower, thus a loss. You will send you a statement staing your profit or loss. You will either get a credit or debit. Check with your remisier if it is T + 3 for payment due. Within this time frame, buy followed by sell is a contra. |
| Useful To Me Not Useful To Me | |
|
|
|
|
timewatch
Senior |
21-Aug-2007 16:43
|
|
x 0
x 0 Alert Admin |
pension can i contra sell with biosensor, have never contra before, so lets say if by example--- i buy biosensor today at 0.62 cents and tomorrow it moves to 0.71 cents can i sell. |
| Useful To Me Not Useful To Me | |
|
timewatch
Senior |
21-Aug-2007 16:37
|
|
x 0
x 0 Alert Admin |
pension, is it again wise to collect at 0.65 cents. thanks |
| Useful To Me Not Useful To Me | |
|
bengster
Member |
21-Aug-2007 14:41
|
|
x 0
x 0 Alert Admin |
Terumo will announce their NOBORI phase 2 results within this couple of weeks. Abbott and Medtronic was in talks several months ago. JNJ came back talking to us in May 2007. Boston approached us in June 2007. That is why im pissed with short term holders dumping this stock for 10 cts gains and affecting the BBs upwards push last week and thus affecting the overall pricing for takeover negotiations. The long-term holder will suffer poorer takeover premiums for the selling actions done by the short term holders. CE and IDE make the rivals know a new and best DES will canibalise their market share but the real push for takeover will be NOBORI phase 2 and LEADERS results. As I say before, they can pay, but they want to see the results first to avoid another Conor disaster. Now price hovering around 70cts. There is a chance takeover offer can go up to $3.50 per share when we have CE, IDE, excellent NOBORI and LEADERS trial results plus Biosensor's strong foothold in Asia. Remember our main contender JNJ is very desperate, got tons of cash and need to protect their DES market share to support their market cap via revival of earnings from their stent division. Failure in their stent business can easily wipe-out US$20B off JNJ's market cap. Warren Buffet wouldn't be happy about that. You don't believe me? Ask Abbott how much in total they paid for Guidant stent division they bought over from Boston couple of years back. Xience stent didn't even have their CE or trial results against Taxus stent then. They are paying over US$4B directly and indirectly for Xience DES. And if NOBORI and LEADERS trial are excellent, BIOMATRIX will be the clinically proven best DES in the world. JW next year forecast earnings at US$25m with China growth story. Ask yourself how much can JW worth if list in Shanghai or NASDAQ next year? Now if you sell for 10 cts profit a few months down the road there is a high chance you will bang balls. When CE comes out, takeover rumours for this stock will be very loud in the market. You can never have a chance to but it cheap again. If you buy it after CE at high price, you have lesser buffer if takeover fails to materialise because your entry price is high also. But don't worry Biosensors have US listing backup plan in place already. I feel there is a high chance CE will come out before end sept 2007. Now trading at IPO price, its freaking dirt cheap. I have reached my limit for this stock. Or else i will be doing some more scooping. Very tempted to buy some more but i need to have discipline. |
| Useful To Me Not Useful To Me | |
|
Pension
Elite |
21-Aug-2007 14:06
|
|
x 0
x 0 Alert Admin |
once it goes below 0.65 cents, you can start to accummulate. |
| Useful To Me Not Useful To Me | |
|
|
|
|
bengster
Member |
20-Aug-2007 23:27
|
|
x 0
x 0 Alert Admin |
Last patient for NOBORI phase 2 was Oct 2006, normally 9 months end-point measurement by normal comparison standard means July 2007 finished 9 months. We give them about one to one and half months for finalising and statisitics. Terumo should be able to announce initial 9 months results about now. They will then present the full details at TCT2007 in Oct 2007. I spoke to the management of Biosensors and i know partial (first 1000 out of 1700 patients) 6 months trial results will most likely be available for presentation on TCT2007. Its going to be stunning. We will cream off Taxus and Cypher like they are just toys for play. After TCT2007, the whole cardio world will look at Biosensors differently. The results will speak for itself. Biomatrix will be the undisputed leader in DES drug and polymer technology. |
| Useful To Me Not Useful To Me | |
|
investor
Senior |
20-Aug-2007 22:19
|
|
x 0
x 0 Alert Admin |
What happen last Friday, was capitulation of the whole mkt, and typically, you can then get to see what are the strong support levels of individual stocks. For Biosensors, the strong support seems to be at 0.58/0.585, which corresponds to the June 2006 lows. No sign of uptrend yet, unless Biosensors can clear and stay above 0.75, and preferably above the recent high of 0.845. On the fundamental front, the last known news about the Nobori phase 2, was that patient enrolment was completed in Oct 2006, therefore it is about time for announcement of its results. HOWEVER, typically, these type of announcements are made at global conferences, and the next one is most likely on 20th Oct 2007. Similarly for the Leaders trial, its 6 mths or 9 mths results will probably also be available around that time. |
| Useful To Me Not Useful To Me | |
|
bengster
Member |
19-Aug-2007 17:18
|
|
x 0
x 0 Alert Admin |
This company will not do share buy back. This company must make full use of the cash to do clinical trials and obtain regulatory approvals to commercialise their products. I believe now the company still have US$77m cash/treasuries/money market after paying US$10m for 50% JW equity. The directors should do some open market purchase in their own capacity but they constantly have news to announce and don't want to be deemed as insider trading as this company's share price is very news driven . In fact, about 2 years back the CEO had to sell some of his shares in open market to settle his USA tax issues after his capital gain tax from the listing of Biosensors in Singapore. I think he is deemed to be domicile in US and hold the green card. The market thought he has no confidence in his own company and share price reacted badly but the fact is that he has not enough cash in his own capacity to pay the over US$10m personal tax liability by US IRA. The investors stopped him in time before he did more ignorant damage to the share price and arranged a financing to settle his US tax payment. |
| Useful To Me Not Useful To Me | |
|
Pension
Elite |
19-Aug-2007 13:45
|
|
x 0
x 0 Alert Admin |
if the company had share buy back option, they should exercise it when the company share start falling, this will frighten of the shortist. |
| Useful To Me Not Useful To Me | |
|
jackjames
Elite |
18-Aug-2007 16:09
|
|
x 0
x 0 Alert Admin |
it's good for us to collect at cheap price .... ..... 
|
| Useful To Me Not Useful To Me | |
|
bengster
Member |
18-Aug-2007 15:44
|
|
x 0
x 0 Alert Admin |
I heard NOBORI (BIOMATRIX) phase 2 trials has excellent results against the current top DES Taxus Liberte from Boston Scientific. In their phase 1 trial, NOBORI win Taxus Express by very wide margins in all endpoint measurements. We have a future DES leader in the making now |
| Useful To Me Not Useful To Me | |
|
bengster
Member |
18-Aug-2007 12:58
|
|
x 0
x 0 Alert Admin |
I told Biosensor's management/directors to do individual open market purchase of Biosensor's shares to show confidence in your own company and send a strong signal to would be shortists. Ridiciously low share price will definitely affect on-going takeover discussions and price negotiations. Weakness in share price now will affect future strength of recovery also. The takeover buyer cannot possibly pay 200% takeover premium as it would be difficult to get their own shareholders to vote for high takeover premium deals as shareholders may deem their Management/Board is over-paying for acquisition. But Biosensors management said with a string of news announcements coming up, they don't want to be caught in a situation where SGX suspect them of insider-trading if they buy near news announcements. At least the management now realise weak share price is a real problem when negotiating takeover deals. Lets hope they do something about it |
| Useful To Me Not Useful To Me | |
|
jerrymaguire
Member |
17-Aug-2007 16:58
|
|
x 0
x 0 Alert Admin |
ya ... i covered at 0.605 ... 0.58 its a strong support, today it made a new low. so next week we can see if any divergence. this counter is a very good shorting counter. volatile and fragile. |
| Useful To Me Not Useful To Me | |